Skip to main content

Table 3 Adjusted mean differences in renal function assessment parameters among patients on TDF and without TDF containing ART

From: The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis

Renal function assessment parameter

Tenofovir (TDF) ART exposure

duration on TDF or non-TDF containing ART

TDF versus non-TDF

P value*

Non-TDF 9 + y versus non-TDF < 9y

TDF < 9y versus non-TDF < 9y

TDF 9 + y versus non-TDF < 9y

P value*

aMD (95 % CI)a

aMD (95 % CI)a

aMD (95 % CI)a

aMD (95 % CI)a

eGFR (Cockcroft-Gault, with BSA adj)

−2.26 (−8.46 to 3.94)

0.472

−2.97 (−13.97 to 8.03)

3.79 (−6.68 to 14.26)

−7.39 (−18.10 to 3.32)

0.200

eGFR (Cockcroft-Gault, without BSA adj)

−2.79 (−14.50 to 8.93)

0.638

−4.40 (−25.21 to 16.42)

1.30 (−18.50 to 21.11)

−8.43 (−28.70 to 11.84)

0.778

eGFR (CKD-Epi)

−0.97 (−3.85 to 1.91)

0.507

−0.32 (−5.44 to 4.79)

2.92 (−1.95 to 7.80)

−2.83 (−7.82 to 2.16)

0.114

eGFR (MDRD with race adj)

−0.30 (−7.58 to 6.98)

0.935

−2.68 (−15.61 to 10.25)

7.26 (−5.05 to 19.57)

−5.77 (−18.37 to 6.83)

0.248

Fractional tubular PO4 reabsorption, % (SD)

−0.47 (−1.54 to 0.61)

0.390

−0.16 (−2.01 to 1.68)

−0.86 (−2.63 to 0.91)

−0.44 (−2.24 to 1.36)

0.786

Urea BUN

0.07 (−0.14 to 0.29)

0.503

−0.05 (−0.43 to 0.33)

0.28 (−0.08 to 0.65)

−0.05 (−0.43 to 0.32)

0.302

Serum creatinine (µmol/L)

2.47 (−0.86 to 5.81)

0.143

−2.51 (−8.44 to 3.42)

−1.53 (−7.17 to 4.12)

1.81 (−3.97 to 7.59)

0.161

Serum phosphates (mmol/L)

0.00 (−0.04 to 0.05)

0.913

−0.01 (−0.09 to 0.08)

0.03 (−0.05 to 0.11)

−0.01 (−0.09 to 0.07)

0.823

  1. BUN blood urea nitrogen, BSA adj body surface area adjustment, race adj race adjustment
  2. * P value showing evidence for adjusted mean differences in renal function parameters by ART regimen type, and duration
  3. aaMD (95 % CI) is adjusted mean difference with 95 % Confidence Interval, adjusted for site, duration on ART for those on non-TDF and duration on TDF among those on TDF, tobacco consumption, socio-economic status index, viral load, CD4 cell counts, hypertension and history of diabetes mellitus or high glucose levels